Reaching consensus on Covid-19 vax patent waiver may take time: Experts

Developed nations opposed the proposal, though it received the support of three-fourths of member nations

Coronavirus vaccine, Covid-19 vaccine, Covid vaccine
Even if there is support from the US, the details of the negotiations are yet to be revealed, which is crucial
Shreya Nandi New Delhi
3 min read Last Updated : May 19 2021 | 6:10 AM IST
As India revises its proposal calling for a temporary patent waiver on Covid-19 vaccines to expedite the discussion at the World Trade Organization (WTO), the path to reaching a consensus could be a long-drawn-out affair, experts said.
 
Experts said that even after consensus is reached among the member countries on waiving sections of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement and the proposal becomes law, implementation will be the key to addressing the shortage vaccines in many countries.
 
RV Anuradha, partner at Clarus Law Associates, said diplomatic negotiations are moving at a slow pace, not keeping the realities of the situation in mind. Besides, the nature and content of the waiver are yet to be known.
 
“In any event, the waiver itself will only be a first step relating to principles of intellectual property. Thereafter begins the nitty-gritty of implementing — how will technology be transferred, who will manufacture, how to ensure supply chains for raw materials and distribution of vaccine after manufacturing. Keeping in mind that the main aim is mass production and distribution of vaccines in the fastest time possible, the implementation, after the consensus on the waiver, is also crucial,” she said.
 
Last October, India and South Africa submitted a joint proposal asking for the waiver of some sections of the TRIPS agreement, including copyrights and patents, to help more countries, especially middle- and low-income nations, access vaccines. Developed nations opposed the proposal, though it received the support of three-fourths of member nations.
 
The recent support shown by the US for a waiver of patent protections on vaccines has been lauded as a great starting point for negotiations, but it continues to face stiff resistance from pharmaceutical lobbies.
 
“Our expectations of better access to technology, vaccines will not happen quickly. There will have to be negotiations at the WTO, which have often taken a lot of time (several years) in the past. Then there are countries that are completely against granting any waiver, which will make it difficult to be resolved at WTO anytime soon. I think there is premature celebration on what this waiver actually means,” said Biswajit Dhar, professor at Jawaharlal Nehru University.
 
Even if there is support from the US, the details of the negotiations are yet to be revealed, which is crucial, Dhar added.
 
Prime Minister Narendra Modi has personally sought the support of leaders of Australia and the European Union for India’s proposal at the WTO. However, there hasn’t been a firm commitment on this from those nations.
 
Last week, WTO Director-General Ngozi Okonjo-Iweala spoke in support of the waiver, expressing hope that countries will start discussions quickly and reach an outcome by the end of the year. “We can’t afford to take months and years to negotiate something. We are talking about lives being lost,” she said.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineWTOHealth Ministry

Next Story